ZIVO · Zivo Bioscience, Inc.
$0.67
At close · Nov 27
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”View the 10-Q filed Nov 14, 2025
Market Cap
$16.53M
Shares
3.89M
Volume · Nov 27
226.8K
Avg daily vol (21 sessions)
42.21K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.67
Open$1.00
Day$0.57–1.11
52W close$0.67–21.84
Avg vol 30d30K
Short int8K · 0.2% float · 4.8d
Short vol35%
DataJan 2020–Nov 2023
Filing10-Q · Nov 14
Up next
filed Nov 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$209,025
Trailing 12 months
Net income (TTM)
−$8.49M
Trailing 12 months
Revenue growth YoY
+108.3%
Year over year
Operating margin
-4,045.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−95%
below
Price vs 50-day avg
−84%
below
RSI (14)
13
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−75%
trailing
6-month return
−96%
trailing
YTD return
−96%
this year
Relative strength
−102%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $13 — 200d above 50d
Institutional flow
Flat
1 of 1 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.21% of float · ▲ +6.6% MoM · 4.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Fundamentals
Revenue growth
+469%
Y/Y
Gross margin
31%
contracting
EPS growth
+8%
Y/Y
Free cash flow
$-4.3M
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
71.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−95%
Bearish
Price vs 50-day avg
−84%
Bearish
RSI (14)
13
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $4 › 200d $13 — 200d above 50d
Institutional flow
Flat
1 of 1 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.21% of float · ▲ +6.6% MoM · 4.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $22
vs 200-day avg -95%
vs 50-day avg -84%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZIVO
this stock
Zivo Bioscience, Inc.
|
$16.53M | — | +468.6% | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.80B | +15.6% | +46.2% | 30.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.3% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.1%
- Reported
- 1 of 1
- Top holder
- CoreCap Advisors, LLC
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZIVO | -47.7% | -74.7% | -95.9% | -75.2% | -95.5% |
| SPY | +0.8% | +10.7% | +6.2% | +8.7% | +18.8% |
| vs SPY | -48.5% | -85.4% | -102.1% | -83.9% | -114.4% |